Who are the Institutional Holders in Moleculin Biotech Inc. (MBRX)?

29 institutions hold shares in Moleculin Biotech Inc. (MBRX), with 1.16M shares held by insiders accounting for 4.09% while institutional investors hold 8.05% of the company’s shares. The shares outstanding are 28.44M, and float is at 27.28M with Short Float at 1.10%. Institutions hold 7.72% of the Float.


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

The top institutional shareholder in the company is Renaissance Technologies, LLC with over 0.16 million shares valued at $0.76 million. The investor’s holdings represent 0.56% of the MBRX Shares outstanding. As of Dec 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 98659.0 shares valued at $0.47 million to account for 0.35% of the shares outstanding. The other top investors are Geode Capital Management, LLC which holds 49086.0 shares representing 0.17% and valued at over $0.23 million, while Truist Financial Corp holds 0.10% of the shares totaling 29167.0 with a market value of $0.14 million.

Moleculin Biotech Inc. (NASDAQ: MBRX) is -19.08% lower on its value in year-to-date trading and has touched a low of $3.14 and a high of $11.82 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MBRX stock was last observed hovering at around $3.93 in the last trading session, with the day’s loss setting it -0.06% off its average median price target of $18.00 for the next 12 months. It is also 86.66% off the consensus price target high of $29.00 offered by 3 analysts, but current levels are 72.36% higher than the price target low of $14.00 for the same period.

Currently trading at $3.87, the stock is -4.89% and -16.42% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.8 million and changing -1.53% at the moment leaves the stock -24.53% off its SMA200. MBRX registered 27.70% gain for a year compared to 6-month loss of -20.24%. The firm has a 50-day simple moving average (SMA 50) of $4.2615 and a 200-day simple moving average (SMA200) of $4.8062.

The stock witnessed a 0.00% gain in the last 1 month and extending the period to 3 months gives it a -24.13%, and is 4.59% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.96% over the week and 6.73% over the month.

Distance from 52-week low is 23.35% and -67.26% from its 52-week high.

Moleculin Biotech Inc. (MBRX) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Moleculin Biotech Inc. (MBRX) is a “Buy”. 3 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Moleculin Biotech Inc. is expected to release its quarterly report on 08/16/2021 and quarterly earnings per share for the current quarter are estimated at -$0.23.The EPS is expected to shrink by -443.60% this year

Moleculin Biotech Inc. (MBRX) Insider Activity

A total of 0 insider transactions have happened at Moleculin Biotech Inc. (MBRX) in the last six months, with sales accounting for 0 and purchases happening 0 times.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Moleculin Biotech Inc. (MBRX): Who are the competitors?

Omeros Corporation (OMER) is 45.92% up on the 1-year trading charts. Short interest in the company’s stock has fallen -38.47% from the last report on Feb 11, 2021 to stand at a total of 0.42 million short shares sold with a short interest ratio of 0.26.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free